Product information and disease description Product description Product information

Access and distribution

3 evidence topics · 4 sources

Summary: access during development

Tovecimig is available only through clinical trials. COMPANION-002 enrolled 168 participants at 34 sites in the United States, is listed as active, not recruiting, and the registry record states that expanded access is not available. Additional access is through investigator-sponsored trials in first-line biliary tract cancer, colorectal cancer, and glioblastoma. Compass Therapeutics holds exclusive global rights outside South Korea, where rights are held by Handok, and Chinese rights are held by Elpiscience; the company states that it may commercialize independently by building an internal sales and marketing organization or through collaborations. The company reported pre-commercialization expenses beginning in 2026 and describes building a commercial organization to support tovecimig in biliary tract cancer. No distribution model, specialty pharmacy arrangement, site-of-care restriction, or expanded access program has been described.

Trial sites and enrollment

“168 patients across 34 sites in the U.S.” (opens the source at this quote in a new tab)

Commercialization plans and territory rights

“We hold worldwide rights to all of our product candidates (with the exception of limited countries for tovecimig), which provide us the optionality to grow our internal pipeline independently or partner selected rights to our product candidates in different geographies throughout the world. Subject to receiving marketing approval, we intend to maximize the value of our product candidates by either independently planning to pursue the commercialization of our products in one or more major geographies by building an internal sales and marketing organization, or by seeking collaborations with third parties with commercialization infrastructure.” (opens the source at this quote in a new tab)

“Building focused commercial organization to support tovecimig in BTC and other future launches” (opens the source at this quote in a new tab)

“This was primarily driven by an increase of $1.4 million of pre-commercialization expenses and $0.8 million of higher stock compensation expense.” (opens the source at this quote in a new tab)

Expanded access program

No evidence found.